Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BioDay Registry: Prospective, Observational Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Diseases in Daily Practice

Next Previous
Trial Profile

BioDay Registry: Prospective, Observational Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Diseases in Daily Practice

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BioDay; Dutch BioDay Registry
  • Sponsors Regeneron Pharmaceuticals; Sanofi

Most Recent Events

  • 13 May 2023 Primary endpoint (The mean EASI and Numeric Rating Scale (NRS)-pruritus after start of tapering) has been met, as per results published in the British Journal of Dermatology.
  • 13 May 2023 Results (n=595) assessing the patient-centered dupilumab dosing regimen in daily practice, to assess prognostic factors for successful tapering and to estimate medication-related cost savings of dupilumab in atopic dermatitis patients, published in the British Journal of Dermatology.
  • 09 Jan 2023 Results (n=38) of sub-analysis and safety analysis assessing effectiveness and safety of upadacitinib on AD and on HE in patients with AD published in the Contact Dermatitis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top